Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
06:45pm, Tuesday, 16'th Jun 2026
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised t
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
12:00pm, Thursday, 11'th Jun 2026
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
10:00am, Thursday, 11'th Jun 2026
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Da
Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping List
06:46pm, Wednesday, 10'th Jun 2026
After not buying or selling any stocks in 2025, a congresswoman who made over $2.4 million in trades in 2024 is buying stocks once again in 2026. Here's a look at the latest transactions.
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
10:29am, Wednesday, 10'th Jun 2026
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“B
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
01:42pm, Tuesday, 09'th Jun 2026
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
09:58am, Monday, 08'th Jun 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
09:00am, Monday, 08'th Jun 2026
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen"
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
01:05pm, Friday, 05'th Jun 2026
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
09:00pm, Thursday, 04'th Jun 2026
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
08:58pm, Thursday, 04'th Jun 2026
LOS ANGELES--(BUSINESS WIRE)---- $BIIB--BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
10:00am, Thursday, 04'th Jun 2026
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Dan
Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
07:30am, Thursday, 04'th Jun 2026
Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced slow
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
01:00am, Thursday, 04'th Jun 2026
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts,
